viewLexagene Holdings Inc.

LexaGene to beta test its rapid pathogen detector at Assurance Scientific Laboratories

The company's LX Analyzer will test urine samples for pathogens and screen for antimicrobial resistance markers

LX Analyzer
The goal is to help clinical laboratories assess the available tools for diagnosing and treating UTIs

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on urine samples.

The company announced an agreement Thursday to place a beta prototype of its LX Analyzer at ASL’s facility in Vestavia, Alabama, which, among other things, tests more than 300 urine samples per week for urinary tract infections (UTIs).

The beta test will focus on detecting pathogens which cause the infections while also screening for genetic markers of antimicrobial resistance — the resistance of bacteria, fungus and viruses to drugs.

READ: LexaGene receives high-level approval from CDC and FDA to test pathogen samples

During the tests, ASL will use the LX Analyzer's open access feature to compare its pathogen detection and antimicrobial resistance characterization technology to ASL’s own. The goal is to help clinical laboratories assess the available tools for diagnosing and treating UTIs.

“This collaborative effort with ASL, a reference laboratory that processes human samples for clinical diagnostic testing, is a perfect example of a laboratory taking advantage of the open-access feature to test the performance of their own assays on our fully automated analyzer,” CEO Jack Regan said in a statement.

“We are excited to have this opportunity to demonstrate the instrument’s capabilities, and how it may someday be used for human clinical diagnostics.”

The company's shared edged 4.4% lower Thurday to C$0.66 on the Venture in Toronto and 3.6% to US$0.50 on OTC Markets.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Lexagene Holdings Inc.

Price: 0.83 CAD

Market: TSX-V
Market Cap: $71.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...



Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

1 week, 1 day ago

2 min read